Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001415889-25-003063
Filing Date
2025-02-04
Accepted
2025-02-04 20:30:15
Documents
1
Period of Report
2025-01-31

Document Format Files

Seq Description Document Type Size
1 form4-02042025_080209.html 4  
1 form4-02042025_080209.xml 4 7799
  Complete submission text file 0001415889-25-003063.txt   9469
Mailing Address 3611 VALLEY CENTRE DR SUITE 300 SAN DIEGO CA 92130
Business Address 3611 VALLEY CENTRE DR SUITE 300 SAN DIEGO CA 92130 888-969-7879
Travere Therapeutics, Inc. (Issuer) CIK: 0001438533 (see all company filings)

EIN.: 262383102 | State of Incorp.: CA | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O TRAVERE THERAPEUTICS, INC. 3611 VALLEY CENTRE DRIVE, SUITE 300 SAN DIEGO CA 92130
Business Address
Heerma Peter (Reporting) CIK: 0001789617 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-36257 | Film No.: 25590413